Compounded tirzepatide: cost, evidence, and the honest comparison
The molecule is tirzepatide, the same dual GIP and GLP-1 agonist found in the approved product — but the finished preparation, its concentration, and any added ingredients come from a compounding pharmacy rather than a manufacturer under FDA review.
What it's approved for
Not an FDA-approved product. Compounded preparations are made by licensed pharmacies for an individual patient under a prescription; the formulation itself is not FDA-reviewed for safety, effectiveness, or manufacturing quality.
Forms and doses: Injectable preparations, and at some providers sublingual drops. Concentrations and vial sizes vary by pharmacy, which is exactly why the source pharmacy matters.
What the research actually shows
No trials exist of compounded formulations themselves; efficacy expectations are borrowed from studies of the approved product. The tirzepatide price gap versus brand direct remains wider than the semaglutide gap, which is the honest case for this route.
Sources: FDA: concerns with unapproved GLP-1 drugs · Stanford Medicine on compounded GLP-1 safety, July 2026
Side effects, stated plainly
Class gastrointestinal effects apply, plus compounding-specific risks: unreviewed formulations, additive combinations the FDA and Stanford clinicians have flagged, and dosing errors when drawing from vials.
What it costs
Compounded tirzepatide undercuts brand tirzepatide by more than compounded semaglutide undercuts brand semaglutide — because LillyDirect has no cheap entry dose the way the Wegovy pill does. That makes this the one compounded category where the price case is still clearly strong.
| Channel | Form & dose | Med | Required fee | True monthly | Status |
|---|---|---|---|---|---|
| TrimiLOWEST LISTED | injection · flat, annual plan only | $125 | — | $125 | listed |
| Cora | injection · flat, annual prepay | $135 | — | $135 | listed |
| Mochi Health | injection · starter dose | $90 | $79/mo | $169 | listed |
| Noom Med | injection · microdose, all-in | $199 | — | $199 | listed |
| Direct Meds | sublingual drops · flat rate | $224 | — | $224 | listed |
| Cora | injection · flat, monthly billing | $225 | — | $225 | listed |
| Shed (ShedRx) | injection · annual plan | $239 | — | $239 | listed |
| Mochi Health | injection · top dose | $199 | $79/mo | $278 | listed |
| Noom Med | injection · full dose, all-in | $299 | — | $299 | listed |
| Shed (ShedRx) | injection · monthly billing | $299 | — | $299 | listed |
| Direct Meds | injection · all-inclusive, month-to-month | $399 | — | $399 | listed |
True monthly = medication plus any required membership fee. Cheapest listed right now: Trimi at $125/month. Full table and filters on the Compounded tirzepatide cost page.
Keep reading
Common questions
Why is compounded tirzepatide a better deal than compounded semaglutide?
Because the brand alternative is pricier. Brand semaglutide now starts at $149 for the oral form, which undercuts most compounded plans, while brand tirzepatide starts at $299 with no cheap entry dose — leaving a wider gap for compounded versions to fill.
Are sublingual drops equivalent to injections?
They are different delivery routes with different absorption, and neither compounded format is FDA-reviewed as formulated. That is a prescriber question, and a reason to ask which pharmacy is compounding it.
Other weight loss medications
Wegovy · Zepbound · Foundayo · Ozempic · Compounded semaglutide · Liraglutide
Compounded tirzepatide market news
The complaint targets sharing sensitive health data with ad platforms and ROSCA billing/cancellation practices — context for anyone weighing the $149/month membership model.
The Hims dossier →Participating Part D plans now cover Wegovy (pen and pill), Foundayo, and the Zepbound KwikPen at a flat $50 monthly copay through 2027 — below every cash price we track.
How the Bridge actually works →The proposed 503B Bulks List exclusion would close the mass-compounding era for good. Patient-specific 503A compounding continues — the legal market our index tracks at $139–$297 all-in.
The surviving market, explained →All tracked news → · Fed by a daily automated scan; entries publish only after primary-source verification.
Educational and pricing journalism, not medical advice — indications, dosing, and suitability are decisions for you and a licensed clinician, and the FDA label is the authority on risks. Prices carry the verification dates shown; the provider's checkout is the final word. Some links may earn commissions; rankings are ordered by cost, never compensation — disclosure.